Beata A Ineck1, Tien M H Ng. 1. Department of Pharmacy Practice, University of Nebraska Medical Center, Omaha, NE 68198-6045, USA.
Abstract
OBJECTIVE: To determine whether the literature supports an effect of subclinical hypothyroidism on serum lipids and, if so, what are the effects of thyroxine replacement therapy. DATA SOURCES: Articles were identified on MEDLINE using the MeSH terms hypothyroidism, lipids, or cholesterol. DATA SYNTHESIS: The majority of studies that determined the prevalence of lipid abnormalities in subclinical hypothyroidism and studies that evaluated the effects of thyroxine replacement on lipids were small, uncontrolled, and varied in inclusion criteria. Six randomized, placebo-controlled trials were identified that evaluated the effect of levothyroxine on lipids in subclinically hypothyroid patients. CONCLUSIONS: Subclinical hypothyroidism can potentially contribute to a pro-atherogenic lipid profile, with effects being greater at higher thyroid-stimulating hormone levels. Thyroxine replacement reduces total cholesterol and low-density lipoprotein cholesterol, with no effect on triglycerides. Effects on high-density lipoprotein, lipoprotein (a), and apolipoproteins A1 and B require further study. Larger prospective studies are needed to clarify many issues.
OBJECTIVE: To determine whether the literature supports an effect of subclinical hypothyroidism on serum lipids and, if so, what are the effects of thyroxine replacement therapy. DATA SOURCES: Articles were identified on MEDLINE using the MeSH terms hypothyroidism, lipids, or cholesterol. DATA SYNTHESIS: The majority of studies that determined the prevalence of lipid abnormalities in subclinical hypothyroidism and studies that evaluated the effects of thyroxine replacement on lipids were small, uncontrolled, and varied in inclusion criteria. Six randomized, placebo-controlled trials were identified that evaluated the effect of levothyroxine on lipids in subclinically hypothyroidpatients. CONCLUSIONS: Subclinical hypothyroidism can potentially contribute to a pro-atherogenic lipid profile, with effects being greater at higher thyroid-stimulating hormone levels. Thyroxine replacement reduces total cholesterol and low-density lipoprotein cholesterol, with no effect on triglycerides. Effects on high-density lipoprotein, lipoprotein (a), and apolipoproteins A1 and B require further study. Larger prospective studies are needed to clarify many issues.
Authors: F Santini; A Marsili; C Mammoli; R Valeriano; G Scartabelli; C Pelosini; M Giannetti; R Centoni; P Vitti; A Pinchera Journal: J Endocrinol Invest Date: 2004-02 Impact factor: 4.256
Authors: Yeo Kyung Lee; Jo Eun Kim; Hyun Ju Oh; Kyung Sun Park; Soo Kyung Kim; Seok Won Park; Moon Jong Kim; Yong Wook Cho Journal: Korean J Intern Med Date: 2011-11-28 Impact factor: 2.884
Authors: Roseane C Marchiori; Luiz A F Pereira; Alexandre A Naujorks; Diego L Rovaris; Daiane F Meinerz; Marta M M F Duarte; João B T Rocha Journal: BMC Endocr Disord Date: 2015-06-23 Impact factor: 2.763
Authors: Ulla Ludwig; Daniela Holzner; Christian Denzer; Artur Greinert; Mark Martin Haenle; Suemeyra Oeztuerk; Wolfgang Koenig; Bernhard Otto Boehm; Richard Andrew Mason; Wolfgang Kratzer; Tilmann Graeter Journal: BMC Endocr Disord Date: 2015-08-15 Impact factor: 2.763